Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | −$0.06 | — | $425.49M | +296.1% | −$0.69 |
| Q1 FY26ended Mar 31, 2026 | May 14, 2026 | −$0.76 | — | $305.96M | +229.6% | −$0.97 |
| Q4 FY25ended Dec 31, 2025 | — | −$1.53 | — | $263.84M | +152.6% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$1.75 | — | $142.34M | +52.4% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$1.70 | — | $107.42M | +18.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$1.42 | — | $92.82M | +22.9% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$1.31 | — | $104.44M | +24.8% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$1.27 | — | $93.43M | +18.2% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Insmed shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$1.94 |
| — |
| $90.34M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$1.06 | — | $75.50M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$1.28 | — | $83.69M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.11 | — | $79.07M | — | — |